Sign in

You're signed outSign in or to get full access.

MR

Manoj Radder

Research Analyst at Jefferies

New York, NY, US

Manoj Radder is an analyst at Jefferies, specializing in equity research with a focus on sectors such as industrials, metals, and materials. While specific companies covered and precise performance metrics are not publicly documented, his role typically involves analysis of major firms within these sectors and providing actionable investment insights to institutional clients. Details on Radder's career timeline, including previous roles or the date he joined Jefferies, as well as professional credentials such as FINRA registrations or notable achievements, are not confirmed in publicly available sources. Radder's expertise is anchored in sector research and advisory within Jefferies' robust investment banking platform.

Manoj Radder's questions to ARVINAS (ARVN) leadership

Question · Q4 2025

Manoj Radder inquired about early observations regarding ARV-393's plasma exposure dynamics when combined with glofitamab, potential dose modifications, and whether recent Roche data has increased interest in vepdegestrant.

Answer

Randy Teel (President and CEO) and Noah Berkowitz (CMO) stated that no dose modifications are anticipated for ARV-393 with glofitamab due to non-overlapping toxicities. Randy Teel confirmed that the recent Roche data validates the ER therapy hypothesis for vepdegestrant and does not pose a concern for its partnership process.

Ask follow-up questions

Fintool

Fintool can predict ARVINAS logo ARVN's earnings beat/miss a week before the call

Manoj Radder's questions to Alkermes (ALKS) leadership

Question · Q3 2025

Manoj Radder asked if Vibrance II top-line data would include time-course data (e.g., 4 vs. 8 weeks), the biological rationale for MWT deterioration seen in other studies, expected dose response in ESS for Vibrance II, and the desired PK profile for next-gen orexin-2 receptor agonists.

Answer

Richard Pops, CEO, stated that Alkermes does not expect to see tachyphylaxis or degradation in efficacy signal. He noted that top-line data might not include detailed time course but emphasized the potential competitive advantage of a range of doses. He declined to disclose specific PK attributes for next-gen orexins, describing them as 'different' for various patient populations.

Ask follow-up questions

Fintool

Fintool can predict Alkermes logo ALKS's earnings beat/miss a week before the call